NCT02816476View on ClinicalTrials.gov

Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

October 5, 2019

Study Completion Date

October 31, 2020

Conditions
Amyloidosis
Interventions
DRUG

Daratumumab

Trial Locations (10)

14000

CHU de Caen, Caen

87042

CHU de Limoges, Limoges

Unknown

CHU d'Angers, Angers

CHU de Lyon Sud, Lyon

APHP - Necker, Paris

APHP - Saint Antoine, Paris

APHP - Saint Louis, Paris

CHU Poitiers, Poitiers

CHU de Rennes, Rennes

Amyloidosis Research and Treatment Center, Pavia

All Listed Sponsors
lead

University Hospital, Limoges

OTHER

NCT02816476 - Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis | Biotech Hunter | Biotech Hunter